Promotion of new clinical dosage forms of five new tumor targeting drugs approved by Hengrui medicine

  According to the information on CFDA website, the clinical evaluation status of irinotecan hydrochloride liposome injection applied for by Hengrui Pharmaceutical (600276 SH) in the research of five new drugs has changed to the completion of certificate preparation - the approval document has been issued Irinotecan is a colon cancer treatment drug Pfizer, the original manufacturer, has an annual income of about US $1 billion At present, including Hengrui medicine, there are three domestic manufacturers of irinotecan common preparations In 2012, Hengrui medical iritecan achieved sales revenue of 300 million yuan, accounting for 6% of the company's operating revenue in that year It is worth mentioning that the liposome formulation is more advanced than the traditional formulation According to the public data, liposome is a kind of artificial membrane, which has the characteristics of biodegradability, non-toxic and non immunogenicity in vivo compared with the common dosage form As a drug carrier, liposome has the targeting property, and can effectively reduce the toxicity and side effects of drugs CFDA shows that at present, there is still a blank in the domestic production enterprises of irinotecan liposome preparation In addition to Hengrui pharmaceutical, two other enterprises are carrying out research and development Guangfa Securities Research Report predicts that the market capacity of irinotecan hydrochloride liposome injection will reach 500 million yuan Come to participate in the discussion of "stealing secret door": [Bion perspective]: Hengrui medicine is involved in stealing trade secrets